nach oben

Erschienen in:

01.05.2011 | Clinical study

Is the angiotensin receptor blocker cancer risk overstated?

Erschienen in: Reactions Weekly | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Excerpt

In June 2010, Sipahi et al. highlighted the risk between angiotensin II receptor blockers (ARBs) and cancer in an article published in the Lancet Oncology.* In contrast to these disturbing results, new data suggest that this risk may be overstated, with two recently published studies independently revealing that there was no significant increase in the overall risk of cancer for recipients of ARBs compared with controls.1, 2 …

The ARB Trialists Collaboration.Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. Journal of Hypertension 29: 623-635, No. 4, Apr 2011. Available from: URL: http://dx.doi.org/10.1097/HJH.0b013e328344a7de

Pasternak B, Svanstrom H, Callreus T, Melbye M, Hviid A.Use of Angiotensin Receptor Blockers and the Risk of Cancer. Circulation 123: 1729-1736, 26 Apr 2011. Available from: URL: http://dx.doi.org/10.1161/CIRCULATIONAHA.110.007336

Titel: Is the angiotensin receptor blocker cancer risk overstated?
Publikationsdatum: 01.05.2011
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2011
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.2165/00128415-201113510-00004

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Is the angiotensin receptor blocker cancer risk overstated?

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Quinine/meloxicam/rofecoxib

Interferon-β-1a

Antineoplastics

News from AAN

Hydrogen peroxide

Linezolid